Tag: ASX: AVR
Anteris marks first successful implantation of DurAVR THV heart valve
ASX-listed biotechnology company Anteris Technologies has announced the successful use of its DurAVR THV biomimetic valve in a valve-in-valve (ViV) procedure.
Anteris awarded utility patent for novel transcatheter heart valve replacement
Australian biotechnology company Anteris Technologies announced that the US Patent and Trademark Office has issued another utility patent for its novel DurAVR transcatheter heart valve (THV).
Anteris Technologies to help develop new heart valve repair solution
Australian biotech company Anteris Technologies has collaborated with v2vmedtech to develop a new heart valve repair device designed for minimally invasive treatment of mitral and tricuspid valve regurgitation.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
FDA OKs manufacturing of Anteris’ aortic valve replacement at Minnesota facility
Anteris Technologies announced that the US Food and Drug Administration (FDA) has approved the manufacturing of DurAVR THV, a 3D single-piece aortic heart valve replacement, at the company's recently expanded production facility in Maple Grove, Minnesota.
Featured Article
Unlock global potential with Bank of Sydney’s trade finance solutions
In an increasingly globalised economy, Australian manufacturers face the dual challenge of managing complex international supply chains while seizing opportunities for global expansion. Trade finance, a crucial financial tool, can help businesses mitigate risks, improve cash flow, and facilitate cross-border trade with confidence.
